Business Context and Reporting Period
This Form 6-K filing by AC Immune SA reports the results of the Annual General Meeting of Shareholders held on June 25, 2021. The filing covers corporate governance actions, including the approval of the 2020 financial statements, appropriation of losses, executive and board compensation, and re-elections.
Key Financial Metrics
The filing references the 2020 financial year results approved by shareholders:
- Net Loss (2020): KCHF 57,824 (approximately CHF 57.8 million).
- Accumulated Losses: The 2020 loss increased the accumulated losses brought forward from KCHF 62,151 to a new balance of KCHF 119,975.
- Revenue, Cash Flow, and Debt: The filing text does not provide specific values for revenue, operating cash flow, debt levels, or liquidity metrics.
Material Changes and Corporate Actions
Shareholders approved several material changes and governance items:
- Financial Approval: Shareholders approved the 2020 Annual Report, Statutory Financial Statements, and IFRS Financial Statements.
- Compensation Caps (FY 2021/2022):
- Board Non-Performance Cash: CHF 689,000.
- Board Equity Grants: CHF 863,000.
- Executive Committee Non-Performance Cash: CHF 3,269,000.
- Executive Committee Variable Cash: CHF 1,378,000.
- Executive Committee Equity Grants: CHF 4,287,000.
- Articles of Association Amendments:
- Amended Article 20 to provide flexibility regarding director nationality, residency, and gender requirements.
- Adjusted the compensation system framework to align with the calendar year.
- Withdrawn Items: The Board withdrew Agenda Items 6.2 ("Authorized Share Capital") and 6.3 ("Conditional Capital Increase for Employee Benefit Plans") prior to the vote.
Guidance, Outlook, and Risks
The filing text does not contain specific financial guidance, forward-looking revenue projections, or detailed risk factors. It notes that the Management presentation to shareholders is attached as Exhibit 99.1, which may contain further operational details. The filing confirms the re-election of the Board of Directors, including Chairman Douglas Williams, and the re-election of PricewaterhouseCoopers SA as Statutory Auditors.
Investor Verification Checklist
- Verify the full 2020 IFRS financial statements (revenue, R&D expenses, and cash burn rate) in the attached Exhibit 99.1 or the company's 20-F filing.
- Review the rationale for withdrawing the "Authorized Share Capital" and "Conditional Capital Increase" agenda items.
- Confirm the impact of the new compensation framework on future equity dilution.
- Assess the company's liquidity position given the accumulated losses of KCHF 119,975.